Ted Slocomb | Managing Partner
TS BioAdvisors

Ted Slocomb is a global commercial and market access biopharma executive with deep experience leading the commercialization of high value rare disease, gene therapy and cell therapy products including leadership roles in new product planning, global market access/pricing, HEOR and global marketing over his 30+ year career. Most recently, Mr. Slocomb was the Vice President, Global Commercial Strategy, Access and Value at Kite Pharma, leading Kite’s integrated global commercial, market access, HEOR and Opinion Leader strategy team. At Kite he also co-chaired the commercial governance for Kite’s alliance with Arcellx for anitocel in multiple myeloma. Prior to Kite, Mr. Slocomb was the Vice President, Global Market Access – Gene Therapies for Astellas and VP, Commercial Planning for Audentes Therapeutics (acquired by Astellas for $3.0B in 2020). Prior roles included Global Commercial Leader for MYALEPTâ at Amylin Pharmaceuticals, Principal at Bear Stearns Health Innoventures, LP and Sr. Director, Corporate Development at Fate Therapeutics. Mr. Slocomb is a former co-chair of the Value & Access Committee of the Alliance for Regenerative Medicine and the Corporate Alliance of Global Genesâ. Mr. Slocomb earned an MBA in Finance from New York University and a BA in Genetics from the University of California, Berkeley.